Corporate Overview

Biomea Fusion is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. An irreversible small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.

Our lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of MENIN, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our proprietary FUSION™ System discovery platform to advance a pipeline of irreversible treatments against other key oncogenic drivers of cancer. Our goal is to utilize our capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers.


Please check back for upcoming events.

SEC Filings

Filing date Description Form

Quarterly report which provides a continuing view of a company's financial position


Initial filing by director officer or owner of more than ten percent.